These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36596858)

  • 1. 2022 FDA approvals.
    Mullard A
    Nat Rev Drug Discov; 2023 Feb; 22(2):83-88. PubMed ID: 36596858
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA new drug approvals in Q1 2021.
    Urquhart L
    Nat Rev Drug Discov; 2021 May; 20(5):334. PubMed ID: 33854219
    [No Abstract]   [Full Text] [Related]  

  • 3. Analysis of Control Arm Quality in Randomized Clinical Trials Leading to Anticancer Drug Approval by the US Food and Drug Administration.
    Hilal T; Sonbol MB; Prasad V
    JAMA Oncol; 2019 Jun; 5(6):887-892. PubMed ID: 31046071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2011 FDA drug approvals.
    Mullard A
    Nat Rev Drug Discov; 2012 Feb; 11(2):91-4. PubMed ID: 22293555
    [No Abstract]   [Full Text] [Related]  

  • 5. Approvals in 2021: dangling Accelerated Approvals, drug dosing, new approvals and beyond.
    Lemery S; Pazdur R
    Nat Rev Clin Oncol; 2022 Apr; 19(4):217-218. PubMed ID: 35136230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significant FDA approvals in 1999.
    McGinnis TJ
    Am Fam Physician; 2000 Apr; 61(8):2531-3. PubMed ID: 10794586
    [No Abstract]   [Full Text] [Related]  

  • 7. U.S. Food and Drug Administration anticancer drug approval trends from 2016 to 2018 for lung, colorectal, breast, and prostate cancer.
    Ribeiro TB; Ribeiro A; Rodrigues LO; Harada G; Nobre MRC
    Int J Technol Assess Health Care; 2020; 36(1):20-28. PubMed ID: 31775939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer Drugs Approved by the US Food and Drug Administration From 2009 to 2020 According to Their Mechanism of Action.
    Olivier T; Haslam A; Prasad V
    JAMA Netw Open; 2021 Dec; 4(12):e2138793. PubMed ID: 34905002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. End points and United States Food and Drug Administration approval of oncology drugs.
    Johnson JR; Williams G; Pazdur R
    J Clin Oncol; 2003 Apr; 21(7):1404-11. PubMed ID: 12663734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-arm clinical trials that supported FDA accelerated approvals have modest effect sizes and were at high risk of bias.
    Ribeiro TB; Colunga-Lozano LE; Araujo APV; Bennett CL; Hozo I; Djulbegovic B
    J Clin Epidemiol; 2022 Aug; 148():193-195. PubMed ID: 35093531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018.
    Ribeiro TB; Buss L; Wayant C; Nobre MRC
    PLoS One; 2020; 15(7):e0236345. PubMed ID: 32706800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of FDA approvals of targeted anticancer combination regimens.
    Brown VT; Cho V; Parkey S
    Am J Health Syst Pharm; 2017 Dec; 74(23):1938-1942. PubMed ID: 29167134
    [No Abstract]   [Full Text] [Related]  

  • 14. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA
    Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Review of novel and supplemental approvals of the targeted cancer drugs by the Food and Drug Administration in 2021.
    Kandemir EA
    J Oncol Pharm Pract; 2023 Jan; 29(1):191-207. PubMed ID: 35793068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New Indications and Approvals for Anticancer Drugs.
    Aschenbrenner DS
    Am J Nurs; 2021 Dec; 121(12):16-17. PubMed ID: 34792500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time from US Food and Drug Administration approval to publication of data for cancer drugs: a comparison of first and subsequent approvals.
    Lammers A; Wang R; Cetnar J; Prasad V
    Blood Cancer J; 2017 Nov; 7(12):637. PubMed ID: 29187747
    [No Abstract]   [Full Text] [Related]  

  • 18. StatBite: FDA oncology drug product approvals in 2009.
    J Natl Cancer Inst; 2010 Feb; 102(4):219. PubMed ID: 20145211
    [No Abstract]   [Full Text] [Related]  

  • 19. FDA approval standards for anticancer agents - lessons from two recent approvals in breast cancer.
    Gyawali B; Kesselheim AS
    Nat Rev Clin Oncol; 2021 Jul; 18(7):397-398. PubMed ID: 33767454
    [No Abstract]   [Full Text] [Related]  

  • 20. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.